Journal of Assisted Reproduction and Genetics

, Volume 34, Issue 11, pp 1537–1545 | Cite as

GnRH antagonist administered twice the day before hCG trigger combined with a step-down protocol may prevent OHSS in IVF/ICSI antagonist cycles at risk for OHSS without affecting the reproductive outcomes: a prospective randomized control trial

  • Yannis Prapas
  • Konstantinos Ravanos
  • Stamatios PetousisEmail author
  • Yannis Panagiotidis
  • Achilleas Papatheodorou
  • Chrysoula Margioula-Siarkou
  • Assunta Iuliano
  • Giuseppe Gullo
  • Nikos Prapas
Assisted Reproduction Technologies



The purpose this study is to investigate whether a double antagonist dose (0.25 mg/12 h) administered the day before hCG trigger is effective in preventing ovarian hyperstimulation syndrome (OHSS) in GnRH antagonist IVF/intracytoplasmic sperm injection (ICSI) cycles at risk for OHSS.


This is a prospective randomized control study, conducted from November 2012 to January 2016. A total of 194 patients undergoing a IVF/ICSI GnRH antagonist cycle that were at risk of OHSS and chose to proceed with embryo transfer and avoid cycle cancellation or embryo cryopreservation were allocated into two groups. The inclusion criteria consisted of a rapid rise of oestradiol ≥ 3500 pg/ml combined with ≥ 18 follicles > 11 mm in diameter without any mature follicle > 16 mm, in any day of stimulation. Overall, 97 patients (intervention group A) received a double dose of GnRH antagonist (0.25 mg/12 h) the day before hCG while 97 patients (control group B) did not. Recombinant FSH administration was tapered to 100 IU/24 h the day of the allocation in both groups.


Incidence of early-onset moderate/severe OHSS was significantly lower in intervention group A compared to control group B (0 vs 12.37%, P < 0.001). Clinical pregnancy rate per cycle (50.52 vs 42.27%, P = 0.249) was not significantly different between the two groups. Oestradiol (3263.471 ± 1271.53 vs 5233 ± 1425.17, P < 0.001), progesterone (0.93 ± 0.12 vs 1.29 ± 0.14, P < 0.001) and luteinizing hormone (1.42 ± 0.31 vs 1.91 ± 0.33, P < 0.001) were significantly lower in group A the day of the hCG triggering.


The administration of a rescue double GnRH antagonist dose the day before hCG trigger may represent a safe alternative preventive strategy for early OHSS without affecting the reproductive outcomes.

Trial registration number



GnRH antagonists OHSS Implantation IVF-ICSI Ovarian stimulation 


  1. 1.
    Al-Inany HG, Abou-Setta AM, Aboulghar M. Gonadotrophin-releasing hormone antagonists for assisted conception: a Cochrane review. Reprod BioMed Online. 2007;14:640–9.CrossRefPubMedGoogle Scholar
  2. 2.
    Griesinger G, Diedrich K, Tarlatzis BC, Kolibianakis EM. GnRH-antagonists in ovarian stimulation for IVF in patients with poor response to gonadotrophins, polycystic ovary syndrome, and risk of ovarian hyperstimulation: a meta-analysis. Reprod BioMed Online. 2006;13:628–38.CrossRefPubMedGoogle Scholar
  3. 3.
    Pundir J, Sunkara SK, El-Toukhy T, Khalaf Y. Meta-analysis of GnRH antagonist protocols: do they reduce the risk of OHSS in PCOS? Reprod BioMed Online. 2012;24:6–22.CrossRefPubMedGoogle Scholar
  4. 4.
    Mathur R, Hayman G, Bansal A, Jenkins J. Serum vascular endothelial growth factor levels are poorly predictive of subsequent ovarian hyperstimulation syndrome in highly responsive women undergoing assisted conception. Fertil Steril. 2002;78:1154–8.CrossRefPubMedGoogle Scholar
  5. 5.
    Papanikolaou EG, Pozzobon C, Kolibianakis EM, et al. Incidence and prediction of ovarian hyperstimulation syndrome in women undergoing gonadotropin-releasing hormone antagonist in vitro fertilization cycles. Fertil Steril. 2006;85:112–20.CrossRefPubMedGoogle Scholar
  6. 6.
    Papanikolaou EG, Humaidan P, Polyzos NP, Tarlatzis B. Identification of the high-risk patient for ovarian hyperstimulation syndrome. Semin Reprod Med. 2010;28:458–62.CrossRefPubMedGoogle Scholar
  7. 7.
    Kol S, Humaidan P. GnRH agonist triggering: recent developments. Reprod BioMed Online. 2013;26:226–30.CrossRefPubMedGoogle Scholar
  8. 8.
    Mansour RT, Aboulghar MA, Serour GI, Amin YM, Abou-Setta AM. Criteria of a successful coasting protocol for the prevention of severe ovarian hyperstimulation syndrome. Hum Reprod. 2005;20:3167–72.CrossRefPubMedGoogle Scholar
  9. 9.
    García-Velasco JA, Isaza V, Quea G, Pellicer A. Coasting for the prevention of ovarian hyperstimulation syndrome: much ado about nothing? Fertil Steril. 2006;85:547–54.CrossRefPubMedGoogle Scholar
  10. 10.
    Engmann L, Benadiva C. Agonist trigger: what is the best approach? Agonist trigger with aggressive luteal support. Fertil Steril. 2012;97:531–3.CrossRefPubMedGoogle Scholar
  11. 11.
    Yu B, Ruman J, Christman G. The role of peripheral gonadotropin-releasing hormone receptors in female reproduction. Fertil Steril. 2011;95:465–73.CrossRefPubMedGoogle Scholar
  12. 12.
    Cheng CK, Yeung CM, Chow BK, Leung PC. Characterization of a new upstream GnRH receptor promoter in human ovarian granulosa-luteal cells. Mol Endocrinol. 2002;16:1552–64.CrossRefPubMedGoogle Scholar
  13. 13.
    Engel JB, Riethmüller-Winzen H, Diedrich K. Extrapituitary effects of GnRH antagonists in assisted reproduction: a review. Reprod BioMed Online. 2005;10:230–4.CrossRefPubMedGoogle Scholar
  14. 14.
    Humaidan P, Kol S, Papanikolaou EG, Copenhagen GnRH Agonist Triggering Workshop Group. GnRH agonist for triggering of final oocyte maturation: time for a change of practice? Hum Reprod Update. 2011;17:510–24.CrossRefPubMedGoogle Scholar
  15. 15.
    Asimakopoulos B, Nikolettos N, Nehls B, Diedrich K, Al-Hasani S, Metzen E. Gonadotropin-releasing hormone antagonists do not influence the secretion of steroid hormones but affect the secretion of vascular endothelial growth factor from human granulosa luteinized cell cultures. Fertil Steril. 2006;86:636–41.CrossRefPubMedGoogle Scholar
  16. 16.
    Prapas Y, Panagiotidis I, Kalogiannidis I, et al. Double GnRH-antagonist dose before HCG administration may prevent OHSS in oocyte-donor cycles: a pilot study. Reprod BioMed Online. 2010;21:159–65.CrossRefPubMedGoogle Scholar
  17. 17.
    Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004;81:19-25.Google Scholar
  18. 18.
    Lainas GT, Kolibianakis EM, Sfontouris IA et al. Pregnancy and neonatal outcomes following luteal GnRH antagonist administration in patients with severe early OHSS. Hum Reprod 2013;28:1929-42Google Scholar
  19. 19.
    Lainas TG,  Sfontouris IA, Zorzovilis IZ et al.  Management of severe OHSS using GnRH antagonist and blastocyst cryopreservation in PCOS patients treated with long protocol. Reprod Biomed Online. 2009b;18(1):15-20.Google Scholar
  20. 20.
    Grossman LC, Michalakis KG, Browne H, Payson MD, Segars JH. The pathophysiology of ovarian hyperstimulation syndrome: an unrecognized compartment syndrome. Fertil Steril. 2010;94:1392-8.Google Scholar
  21. 21.
    Golan A, Ron-el R, Herman A, Soffer Y, Weinraub Z, Caspi E. Ovarian hyperstimulation syndrome: an update review. Obstet Gynecol Surv. 1989;44(6):430-40. Google Scholar
  22. 22.
    Lainas TG, Sfontouris IA, Zorzovilis IZ, Petsas GK, Lainas GT, Kolibianakis EM. Management of severe early ovarian hyperstimulation syndrome by re-initiation of GnRH antagonist. Reprod Biomed Online. 2007;15:408-12.Google Scholar
  23. 23.
    Griesinger G, Berndt H, Schultz L, Depenbusch M, Schultze-Mosgau A. Cumulative live birth rates after GnRH-agonist triggering of final oocyte maturation in patients at risk of OHSS: a prospective, clinical cohort study. Eur J Obstet Gynecol Reprod Biol. 2010;149:190–4.Google Scholar
  24. 24.
    Gardner DK, Lane M, Stevens J, Schlenker T, Schoolcraft WB. Blastocyst score affects implantation and pregnancy outcome: towards a single blastocyst transfer. Fertil Steril. 2000;73(6):1155-8. Google Scholar
  25. 25.
    Griesinger G, Berndt H, Schultz L, Depenbusch M, Schultze-Mosgau A. Cumulative live birth rates after GnRH-agonist triggering of final oocyte maturation in patients at risk of OHSS: a prospective, clinical cohort study. Eur J Obstet Gynecol Reprod Biol. 2010;149:190-4.Google Scholar
  26. 26.
    Kolibianakis EM, Venetis CA, Bontis J, Tarlatzis BC. Significantly lower pregnancy rates in the presence of progesterone elevation in patients treated with GnRH antagonists and gonadotrophins: a systematic review and meta-analysis. Curr Pharm Biotechnol. 2012;13:464-70.Google Scholar
  27. 27.
    Manzanares MA, Gómez-Palomares JL, Ricciarelli E, Hernández ER. Triggering ovulation with gonadotropin-releasing hormone agonist in in vitro fertilization patients with polycystic ovaries does not cause ovarian hyperstimulation syndrome despite very high estradiol levels. Fertil Steril. 2010;93:1215-9.Google Scholar
  28. 28.
    Gustofson RL, Segars JH, Larsen FW. Ganirelix acetate causes a rapid reduction in estadiol levels without adversely affecting oocyte maturation in women pretreated with leuprolide acetate who are at risk of ovarian hyperstimulation syndrome. Hum Reprod. 2006;21:2830-7.Google Scholar
  29. 29.
    Aboulghar MA, Mansour RT, Amin YM, Al-Inany HG, Aboulghar MM, Serour GI. A prospective randomized study comparing coasting with GnRH antagonist administration in patients at risk for severe OHSS. Reprod Biomed Online. 2007;15:271-9.Google Scholar
  30. 30.
    Hill MJ, Chason RJ, Payson MD, Segars JH, Csokmay JM. GnRH antagonist rescue in high responders at risk for OHSS results in excellent assisted reproduction outcomes. Reprod Biomed Online. 2012;25:284-91.Google Scholar
  31. 31.
    Minaretzis D, Jakubowski M, Mortola JF, Pavlou SN. Gonadotropin-releasing hormone receptor gene expression in human ovary and granulosa-lutein cells. J Clin Endocrinol Metab. 1995;80(2):430-4.Google Scholar
  32. 32.
    Hillensjö T, LeMaire WJ. Gonadotropin releasing hormone agonists stimulate meiotic maturation of follicle-enclosed rat oocytes in vitro. Nature. 1980;287(5778):145-6.Google Scholar
  33. 33.
    Singh P, Krishna A. Effects of GnRH agonist treatment on steroidogenesis and folliculogenesis in the ovary of cyclic mice. J Ovarian Res. 2010;3:26.Google Scholar
  34. 34.
    Singh P, Krishna A. Effects of GnRH agonist treatment on steroidogenesis and folliculogenesis in the ovary of cyclic mice. J Ovarian Res. 201;3:26.Google Scholar
  35. 35.
    Bonilla-Musoles FM, Raga F, Castillo JC, Sanz M, Dolz M, Osborne N. High doses of GnRH antagonists are efficient in the management of severe ovarian hyperstimulation syndrome. Clin Exp Obstet Gynecol. 2009;36(2):78-81.Google Scholar
  36. 36.
    Ding LJ, Wang B, Shen XY et al. Withdrawal of GnRH agonist decreases oestradiol and VEGF concentrations in high responders. Reprod Biomed Online. 2013;27:131-9.Google Scholar
  37. 37.
    Aboulghar MA. Prediction of ovarian stimulation syndrome (OHSS). Estradiol levels has an important role in the prediction of OHSS. Hum Reprod. 2003;18:1140-1.Google Scholar
  38. 38.
    Centurione L, Giampietro F, Sancilio S et al. Morphometric and ultrastructural analysis of human granulosa cells after gonadotrophin-releasing hormone agonist or antagonist. Reprod Biomed Online. 2010;20:625-33.Google Scholar
  39. 39.
    Khalaf M, Mittre H, Levallet J et al. GnRH agonist and GnRH antagonist protocols in ovarian stimulation: differential regulation pathway of aromatase expression in human granulosa cells. Reprod Biomed Online. 2010;21:56-65.Google Scholar
  40. 40.
    Lindheim SR, Morales AJ. GnRH antagonists followed by a decline in serum estradiol results in adverse outcomes in donor oocyte cycles. Hum Reprod. 2003;10:2048-2051.Google Scholar
  41. 41.
    Fisher S, Grin A, Paltoo A et al. Falling estradiol levels as a result of intentional reduction in gonadotrophin dose are not associated with poor IVF outcomes, whereas spontaneously falling estradiol levels result in low clinical pregnancy rates. Hum Reprod. 2005;20:84-8.Google Scholar
  42. 42.
    Abdalla H, Nicopoulos JD. The effect of duration of coasting and estradiol drop on the outcome of assisted reproduction: 13 years of experience in 1068 coasted cycles to prevent ovarian hyperstimulation. Fertil Steril. 2010;94:1757-63.Google Scholar
  43. 43.
    Dovey S, McIntyre K, Jacobson D, Catov J, Wakim A. Is a premature rise in luteinizing hormone in the absence of increased progesterone levels detrimental to pregnancy outcome in GnRH antagonist in vitro fertilization cycles. Fertil Steril. 2011;96:585-589.Google Scholar
  44. 44.
    Doody KJ, Devroey P, Leader A, Witjes H, Mannaerts BM. No association between endogenous LH and pregnancy in a GnRH antagonist protocol: part I, corifollitropin alfa. Reprod Biomed Online. 2011;23:449-456.Google Scholar
  45. 45.
    Griesinger G, Schultz L, Bauer T et al. Ovarian hyperstimulation syndrome prevention by gonadotropin-releasing hormone agonist triggering of final oocyte maturation in a gonadotropin-releasing hormone antagonist protocol in combination with a "freeze-all" strategy: a prospective multicentric study. Fertil Steril. 2011;95:2029-33.Google Scholar
  46. 46.
    de Ziegler D. Hormonal control of endometrial receptivity. Hum Reprod. 1995;10:4-7.Google Scholar
  47. 47.
    The Ganirelix Dose-Finding Study Group. A double-blind, randomized, does-finding study to assess the efficacy of the gonadotropin-releasing hormone antagonist ganirelix (Org 37462) to prevent premature luteinization hormone surges in women undergoing ovarian stimulation with recombinant follicle stimulating hormone. Hum Reprod. 1998;13:3023-3031.Google Scholar
  48. 48.
    .Fauser BC, Devroey P. 2005 Why is the clinical acceptance of gonadotrophin-releasing hormone antagonist co-treatment during ovarian hyperstimulation for in vitro fertilization so slow? Fertil Steril. 2005;83:1607-11.Google Scholar
  49. 49.
    Hernandez ER. Embryo implantation: the Rubicon for GnRH antagonists. Hum Reprod. 2000;15:211-1216.Google Scholar
  50. 50.
    Huirne JAF. Dose-finding study of daily GnRH antagonist for the prevention of premature LH surges in IVF/ICSI patients: optimal changes in LH and progesterone for clinical pregnancy. Human Reproduction. 2004;20(2):359-367.Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2017

Authors and Affiliations

  • Yannis Prapas
    • 1
  • Konstantinos Ravanos
    • 1
  • Stamatios Petousis
    • 1
    Email author
  • Yannis Panagiotidis
    • 1
  • Achilleas Papatheodorou
    • 1
  • Chrysoula Margioula-Siarkou
    • 1
  • Assunta Iuliano
    • 2
  • Giuseppe Gullo
    • 3
  • Nikos Prapas
    • 1
  1. 1.IAKENTRO Fertility CentreThessalonikiGreece
  2. 2.Azienda Ospedaliera San CarloPotenzaItaly
  3. 3.Dipartimento di Ostetricia e GinecologiaPoliclinico P. Giaccone-Universita degli studi di PalermoPalermoItaly

Personalised recommendations